Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment

Journal of Drug Targeting

Volumn 19, Issue 10, 2011, Pages 915-924

  Gormley, Adam J ^a   Malugin, Alexander ^a   Ray, Abhijit ^a   Robinson, Ryan ^a   Ghandehari, Hamidreza ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Angiogenesis targeting; Gold nanorods; Prostate cancer; RGD

Indexed keywords

ARGINYLGLYCYLGLYCYLPHENYLALANYLLYSINE; GOLD NANOROD; MACROGOL; NANOROD; PENTAPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DARK FIELD MICROSCOPY; DRUG BINDING; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MICROSCOPY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL LINE, TUMOR; FEMALE; GOLD; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTUBES; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; SPECTROPHOTOMETRY, ATOMIC; SULFHYDRYL COMPOUNDS; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81255143358     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.623701     Document Type: Article

References (74)

1. Aragnol D, Leserman LD. (1986). Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA, 83, 2699-2703. (Pubitemid 16026951)
2. Arnida, Janát-Amsbury MM, Ray A, Peterson CM, Ghandehari H. (2011). Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm, 77, 417-423.
3. Arosio D, Manzoni L, Araldi EM, Scolastico C. (2011). Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug Chem, 22, 664-672.
4. Borgman MP, Aras O, Geyser-Stoops S, Sausville EA, Ghandehari H. (2009a). Biodistribution of HPMA copolymer-aminohexylgeldanamycin- RGDfK conjugates for prostate cancer drug delivery. Mol Pharm, 6, 1836-1847.
5. Borgman MP, Coleman T, Kolhatkar RB, Geyser-Stoops S, Line BR, Ghandehari H. (2008). Tumor-targeted HPMA copolymer- (RGDfK)-(CHX-A"-DTPA) conjugates show increased kidney accumulation. J Control Release, 132, 193-199.
6. Borgman MP, Ray A, Kolhatkar RB, Sausville EA, Burger AM, Ghandehari H. (2009b). Targetable HPMA copolymeraminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm Res, 26, 1407-1418.
7. Breuer O, Sundararaj U. (2004). Big returns from small fibers: A review of polymer/carbon nanotube composites. Polymer Composites, 25, 630-645. (Pubitemid 40002560)
8. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, Gambhir SS, Chen X. (2006). Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett, 6, 669-676.
9. Chen J, Saeki F, Wiley BJ, Cang H, Cobb MJ, Li ZY, Au L, Zhang H, Kimmey MB, Li X, Xia Y. (2005). Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett, 5, 473-477. (Pubitemid 40449718)
10. Chithrani BD, Chan WC. (2007). Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett, 7, 1542-1550. (Pubitemid 47140422)
11. Chithrani BD, Ghazani AA, Chan WC. (2006). Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett, 6, 662-668.
12. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. (2005). Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 1, 325-327. (Pubitemid 43951781)
13. Copland JA, Eghtedari M, Popov VL, Kotov N, Mamedova N, Motamedi M, Oraevsky AA. (2004). Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol, 6, 341-349. (Pubitemid 39243067)
14. Dickerson EB, Dreaden EC, Huang X, El-Sayed IH, Chu H, Pushpanketh S, McDonald JF, El-Sayed MA. (2008). Gold nanorod assisted nearinfrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett, 269, 57-66.
15. Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC. (2007). Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging, 34, 267-273. (Pubitemid 46147510)
16. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. (2006). Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem, 17, 603-609. (Pubitemid 43794369)
17. Dudar TE, Jain RK. (1984). Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res, 44, 605-612. (Pubitemid 14187461)
18. Duncan R. (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2, 347-360. (Pubitemid 37361705)
19. El-Sayed IH, Huang X, El-Sayed MA. (2005). Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett, 5, 829-834. (Pubitemid 40749040)
20. Gabizon A, Papahadjopoulos D. (1992). The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta, 1103, 94-100.
21. Gormley AJ, Ghandehari H. (2009). Evaluation of toxicity of nanostructures in biological systems. In: Sahu SC & Casciano DA ed. Nanotoxicity: From In Vivo and In Vitro Models to Health Risks. West Sussex: Wiley, 115-159.
22. Gormley AJ, Greish K, Ray A, Robinson R, Gustafson JA, Ghandehari H. (2011). Gold nanorod mediated plasmonic photothermal therapy: a tool to enhance macromolecular delivery. Int J Pharm, 415, 315-318.
23. Greish K, Ray A, Bauer H, Larson N, Malugin A, Pike D, Haider M, Ghandehari H. (2011). Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release, 151, 263-270.
24. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. (2003). Nanoshell-mediated nearinfrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA, 100, 13549-13554. (Pubitemid 37444779)
25. Horsman MR. (2006). Tissue physiology and the response to heat. Int J Hyperthermia, 22, 197-203. (Pubitemid 43878679)
26. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. (2007). Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond), 2, 681-693. (Pubitemid 350268247)
27. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. (2008). Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci, 23, 217-228.
28. Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA, Nie S. (2010). A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano, 4, 5887-5896.
29. Iyer AK, Khaled G, Fang J, Maeda H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 11, 812-818. (Pubitemid 44280021)
30. Jain PK, El-Sayed IH, El-Sayed MA. (2007). Au nanoparticles target cancer. Nano Today, 2, 18-29. (Pubitemid 46196541)
31. Kelly KL, Coronado E, Zhao LL, Schatz GC. (2003). The optical properties of metal nanoparticles: the influence of size, shape, and dielectric environment. J Phys Chem B, 107, 668-677.
32. Khan JA, Pillai B, Das TK, Singh Y, Maiti S. (2007). Molecular effects of uptake of gold nanoparticles in HeLa cells. Chembiochem, 8, 1237-1240. (Pubitemid 47171988)
33. Kopecek J, Kopecková P. (2010). HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev, 62, 122-149.
34. Kumar CC, Nie H, Rogers CP, Malkowski M, Maxwell E, Catino JJ, Armstrong L. (1997). Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther, 283, 843-853. (Pubitemid 27514647)
35. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. (2002). Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm, 240, 95-102. (Pubitemid 34607706)
36. Li M, Schnablegger H, Mann S. (1999). Coupled synthesis and selfassembly of nanoparticles to give structures with controlled organization. Phys Rev Lett, 82, 1345-1349.
37. Li Z, Huang P, Zhang X, Lin J, Yang S, Liu B, Gao F, Xi P, Ren Q, Cui D. (2010). RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. Mol Pharm, 7, 94-104.
38. Line BR, Mitra A, Nan A, Ghandehari H. (2005). Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med, 46, 1552-1560. (Pubitemid 46173267)
39. Loo C, Lowery A, Halas N, West J, Drezek R. (2005). Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett, 5, 709-711. (Pubitemid 40609745)
40. Maeda H, Greish K, Fang J. (2006). The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Adv Polymer Sci, 193, 103-121.
41. Mao Z, Wang B, Ma L, Gao C, Shen J. (2007). The influence of polycaprolactone coating on the internalization and cytotoxicity of gold nanoparticles. Nanomedicine, 3, 215-223. (Pubitemid 47332343)
42. Maruyama K, Ishida O, Takizawa T, Moribe K. (1999). Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev, 40, 89-102. (Pubitemid 29486606)
43. Matsumura Y, Kataoka K. (2009). Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci, 100, 572-579.
44. Mitra A, Coleman T, Borgman M, Nan A, Ghandehari H, Line BR. (2006a). Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. J Control Release, 114, 175-183. (Pubitemid 44291848)
45. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. (2005). Targeting tumor angiogenic vasculature using polymer- RGD conjugates. J Control Release, 102, 191-201. (Pubitemid 40093785)
46. Mitra A, Nan A, Papadimitriou JC, Ghandehari H, Line BR. (2006b). Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol, 33, 43-52. (Pubitemid 43184077)
47. Narayanan R, El-Sayed MA. (2005). Catalysis with transition metal nanoparticles in colloidal solution: nanoparticle shape dependence and stability. J Phys Chem B, 109, 12663-12676. (Pubitemid 41004923)
48. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, Katayama Y, Niidome Y. (2006). PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release, 114, 343-347. (Pubitemid 44310822)
49. Nikoobakht B, El-Sayed MA. (2003). Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated growth method. Chem Mater, 15, 1957-1962.
50. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. (2004). Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett, 209, 171-176. (Pubitemid 38670486)
51. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol, 15, 440-449. (Pubitemid 38444547)
52. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. (2004). Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv, 11, 169-183. (Pubitemid 38720414)
53. Pasqualini R, Koivunen E, Ruoslahti E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol, 15, 542-546. (Pubitemid 27251571)
54. Peeters PAM, Storm G, Crommelin DJA. (1988). Immunoliposomes in vivo: state of the art. Adv Drug Deliv Rev, 1, 249-266.
55. Ray A, Larson N, Pike DB, Grüner M, Naik S, Bauer H, Malugin A, Greish K, Ghandehari H. (2011). Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm, 8, 1090-1099.
56. Rhim JS, Tsai WP, Chen ZQ, Chen Z, Van Waes C, Burger AM, Lautenberger JA. (1998). A human vascular endothelial cell model to study angiogenesis and tumorigenesis. Carcinogenesis, 19, 673-681. (Pubitemid 28376813)
57. Romanov VI, Goligorsky MS. (1999). RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate, 39, 108-118. (Pubitemid 29194282)
58. Ruoslahti E, Pierschbacher MD. (1987). New perspectives in cell adhesion: RGD and integrins. Science, 238, 491-497. (Pubitemid 17147032)
59. Sadekar S, Ray A, Janàt-Amsbury M, Peterson CM, Ghandehari H. (2011). Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules, 12, 88-96.
60. Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, Tilley WD, Horsfall DJ. (2003). Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res, 63, 4786-4791. (Pubitemid 37022606)
61. Salem AK, Searson PC, Leong KW. (2003). Multifunctional nanorods for gene delivery. Nat Mater, 2, 668-671.
62. Schwartz JA, Shetty AM, Price RE, Stafford RJ, Wang JC, Uthamanthil RK, Pham K, McNichols RJ, Coleman CL, Payne JD. (2009). Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res, 69, 1659-1667.
63. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. (2005). Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir, 21, 10644-10654. (Pubitemid 41692144)
64. Skebo JE, Grabinski CM, Schrand AM, Schlager JJ, Hussain SM. (2007). Assessment of metal nanoparticle agglomeration, uptake, and interaction using high-illuminating system. Int J Toxicol, 26, 135-141. (Pubitemid 46514925)
65. Song CW, Kang MS, Rhee JG, Levitt SH. (1980). Effect of hyperthermia on vascular function in normal and neoplastic tissues. Ann N Y Acad Sci, 335, 35-47.
66. Stern JM, Stanfield J, Kabbani W, Hsieh JT, Cadeddu JA. (2008). Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol, 179, 748-753.
67. Thumshirn G, Hersel U, Goodman SL, Kessler H. (2003). Multimeric cyclic RGD peptides as potential tools for tumor targeting: solidphase peptide synthesis and chemoselective oxime ligation. Chemistry, 9, 2717-2725.
68. Tkachenko AG, Xie H, Liu Y, Coleman D, Ryan J, Glomm WR, Shipton MK, Franzen S, Feldheim DL. (2004). Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem, 15, 482-490. (Pubitemid 38657853)
69. Tong L, Wei Q, Wei A, Cheng JX. (2009). Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal effects. Photochem Photobiol, 85, 21-32.
70. Vainrub A, Pustovyy O, Vodyanoy V. (2006). Resolution of 90 nm (lambda/5) in an optical transmission microscope with an annular condenser. Opt Lett, 31, 2855-2857. (Pubitemid 44600092)
71. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, Agarwal RG, Lam KS. (2011). The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials, 32, 3435-3446.
72. Xie H, Diagaradjane P, Deorukhkar AA, Goins B, Bao A, Phillips WT, Wang Z, Schwartz J, Krishnan S. (2011). Integrin ?v ?3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine, 6, 259-269.
73. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, Xie J, Kim C, Song KH, Schwartz AG, Wang LV, Xia Y. (2009). Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater, 8, 935-939.
74. Zarabi B, Borgman MP, Zhuo J, Gullapalli R, Ghandehari H. (2009). Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm Res, 26, 1121-1129.